4 research outputs found
The Longest Amyloid‑β Precursor Protein Intracellular Domain Produced with Aβ42 Forms β‑Sheet-Containing Monomers That Self-Assemble and Are Proteolyzed by Insulin-Degrading Enzyme
Alzheimer’s
disease (AD) is the most common neurodegenerative disease resulting
in dementia. It is characterized pathologically by extracellular amyloid
plaques composed mainly of deposited Aβ42 and intracellular
neurofibrillary tangles formed by hyperphosphorylated tau protein.
Recent clinical trials targeting Aβ have failed, suggesting
that other polypeptides produced from the amyloid-β precursor
protein (APP) may be involved in AD. An attractive polypeptide is
AICD57, the longest APP intracellular domain (AICD) coproduced with
Aβ42. Here, we show that AICD57 forms micelle-like assemblies
that are proteolyzed by insulin-degrading enzyme (IDE), indicating
that AICD57 monomers are in dynamic equilibrium with AICD57 assemblies.
The N-terminal part of AICD57 monomer is not degraded, but its C-terminal
part is hydrolyzed, particularly in the YENPTY motif that has been
associated with the hyperphosphorylation of tau. Therefore, sustaining
IDE activity well into old age holds promise for regulating levels
of not only Aβ but also AICD in the aging brain
Differential Effects of Polyphenols on Insulin Proteolysis by the Insulin-Degrading Enzyme
The insulin-degrading enzyme (IDE) possesses a strong ability to degrade insulin and Aβ42 that has been linked to the neurodegeneration in Alzheimer’s disease (AD). Given this, an attractive IDE-centric strategy for the development of therapeutics for AD is to boost IDE’s activity for the clearance of Aβ42 without offsetting insulin proteostasis. Recently, we showed that resveratrol enhances IDE’s activity toward Aβ42. In this work, we used a combination of chromatographic and spectroscopic techniques to investigate the effects of resveratrol on IDE’s activity toward insulin. For comparison, we also studied epigallocatechin-3-gallate (EGCG). Our results show that the two polyphenols affect the IDE-dependent degradation of insulin in different ways: EGCG inhibits IDE while resveratrol has no effect. These findings suggest that polyphenols provide a path for developing therapeutic strategies that can selectively target IDE substrate specificity